公开(公告)号：US08653081B2

公开(公告)日：2014-02-18

申请号：US13853352

申请日：2013-03-29

Applicant: Cytokinetics, Inc.

Inventor： Bradley P. Morgan ,  Erica A. Kraynack ,  Pu-Ping Lu ,  Alex Muci ,  David J. Morgans

IPC: A61K31/496 ,  C07D413/14

CPC classification number: C07D413/12 ,  C07D213/75 ,  C07D295/13 ,  C07D295/145 ,  C07D401/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Abstract translation: 某些取代的脲衍生物选择性地调节心肌肉瘤，例如通过增强心肌肌球蛋白，并且可用于治疗包括充血性心力衰竭的收缩性心力衰竭。

公开(公告)号：US20130324549A1

公开(公告)日：2013-12-05

申请号：US13897086

申请日：2013-05-17

Applicant: Cytokinetics, Inc.

Inventor： Bradley P. MORGAN ,  David J. Morgans ,  Alex Muci ,  Pu-Ping Lu ,  Erica A. Kraynack ,  Todd Tochimoto

IPC: C07D213/75

CPC classification number: C07D213/75 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/5377

Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Abstract translation: 某些取代的脲衍生物选择性地调节心肌肉瘤，例如通过增强心肌肌球蛋白，并且可用于治疗包括充血性心力衰竭的收缩性心力衰竭。

公开(公告)号：US12264133B2

公开(公告)日：2025-04-01

申请号：US17452025

申请日：2021-10-22

Applicant: Cytokinetics, Inc.

Inventor： Bradley Paul Morgan ,  Alex Muci ,  Pu-Ping Lu ,  Todd Tochimoto ,  David J. Morgans, Jr. ,  Erica Anne Kraynack

IPC: C07D241/04 ,  C07D211/56 ,  C07D213/75 ,  C07D239/42 ,  C07D261/14 ,  C07D263/48 ,  C07D271/113 ,  C07D295/26 ,  C07D401/10 ,  C07D401/12 ,  C07D417/00 ,  C07D417/10 ,  C07D417/12 ,  C07D487/04 ,  C07D491/04 ,  C07D513/04

Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

公开(公告)号：US11981644B2

公开(公告)日：2024-05-14

申请号：US17453761

申请日：2021-11-05

Applicant: Cytokinetics, Inc.

Inventor： Bradley P. Morgan ,  Chris Evans ,  Pu-Ping Lu ,  Makoto Yamasaki ,  Wenyue Wang ,  Scott Collibee ,  Takuya Makino ,  Kazuyuki Tsuchiya ,  Toshio Kurosaki ,  Susumu Yamaki ,  Eriko Honjo ,  Yuka Koizumi ,  Naoto Katoh ,  Ryuichi Sekioka ,  Ikumi Kuriwaki

IPC: C07D243/14 ,  C07D401/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/08 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D498/04 ,  C07D519/00

CPC classification number: C07D243/14 ,  C07D401/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/08 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D498/04 ,  C07D519/00 ,  C07B2200/13

Abstract: Provided herein are compounds of formula (1):




or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

公开(公告)号：US10975034B2

公开(公告)日：2021-04-13

申请号：US16459754

申请日：2019-07-02

Applicant: Cytokinetics, Inc.

Inventor： Bradley Paul Morgan ,  Alex Muci ,  Pu-Ping Lu ,  Erica Anne Kraynack ,  Todd Tochimoto ,  David J. Morgans, Jr.

IPC: C07D213/75 ,  C07D417/00 ,  C07D417/12 ,  C07D513/04 ,  C07D491/04 ,  C07D487/04 ,  C07D417/10 ,  C07D211/56 ,  C07D401/10 ,  C07D295/26 ,  C07D271/113 ,  C07D263/48 ,  C07D261/14 ,  C07D239/42 ,  C07D401/12

Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.